(Q28302584)

https://api.crossref.org/works/10.2146%2FAJHP080461

Novel treatment strategies for malignant melanoma: a new beginning?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080461

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080461

Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080461

The role of B-RAF in melanoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080461

Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080461

The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080461

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080461

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080461

Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080461

Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080461

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080461

High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080461

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080461

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080461

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080461

Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080461

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080461

Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080461

Immunotherapeutic strategies for high-risk bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080461

Adjuvant therapy of malignant melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080461

Stress proteins and the immune response

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080461

Cancer vaccine--Antigenics

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080461

HSPPC-96: a personalised cancer vaccine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080461

Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080461